Document is current

Article History

Received: 25 April 2023

Accepted: 9 July 2024

First Online: 25 July 2024

Declarations

:

: The authors have no conflicts of interest to report related to this work. Outside the work presented in this paper, PRN provides consultancy services for Roche, Cerveau Radiopharmaceuticals, Lilly, Eisai, Pfizer, and Novo Nordisk. He also serves as a clinical trials investigator for Biogen, Novo Nordisk, and Biogen. SG is a member of the scientific advisory boards of Alzheon, AmyriAD, Eisai Canada, Enigma USA, Lilly Canada, Medesis, Okutsa Canada, Roche Canada, and TauRx. He is a member of the editorial board of JPAD and of the Neurotorium. He has given lectures under the auspices of Biogen Canada and Lundbeck Korea. HZ has served on scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant and on advisory boards for Acumen, ALZPath, BioArctic, Biogen, Eisai, Julius Clinical, Lilly, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for Biogen, Eisai and Roche Diagnostics; and is a member of the editorial board of Alzheimer’s Research & Therapy and a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. NJA serves as an associate editor of Alzheimer’s Research & Therapy.